Release details

2018-12-17 07:00 CET
  • Print
  • Share Share
fi en

Revenio Group Corporation: Revenio Group's financial reporting and annual general meeting in 2019

Revenio Group Corporation, Stock Exchange Release, December 17, 2018 at 8:00   


During 2019, Revenio Group Corporation will publish the following financial reports:

  • Financial Statements bulletin in regard to 2018 on Thursday, February 14, 2019
  • Interim Report 1-3/2019 on Wednesday, April 17, 2019
  • Interim Report 1-6/2019 on Monday, August 5, 2019
  • Interim Report 1-9/2019 on Thursday, October 24, 2019

Due to an amendment in the Securities Market Act, which came into force on 26 November 2015, Revenio will publish the descriptive sections of its interim reports for 1-3/2019 and 1-9/2019 in a concise form. The table sections will be reported in accordance with previous practices.

The Annual General Meeting is planned to be held on Wednesday, March 20, 2019. The Board of Directors will give a separate notice of the Annual General Meeting later.

A shareholder, who wishes to place an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 4, 2019. Such requests including the reasoning or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.

The Annual Report for 2018 will be published on the Group's website during week 9 in 2019.

Revenio Group Corporation

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2017, net sales of Revenio Group totaled MEUR 26.8, with an operating margin of 35.5%, excluding non-recurring expenses. Revenio Group Corporation is listed on Nasdaq Helsinki.